<DOC>
	<DOCNO>NCT00504452</DOCNO>
	<brief_summary>The primary purpose study investigate safety efficacy KP-1461 give every 12 hour 124 day HIV+ patient fail multiple antiretroviral regimen .</brief_summary>
	<brief_title>Safety Efficacy Study KP-1461 Treat ART-Experienced HIV+ Patients</brief_title>
	<detailed_description>KP-1461 prodrug KP-1212 triphosphate , unique nucleoside incorporate HIV viral genome result accumulation nucleic substitution interfere viral replication . The study design investigate safety antiviral activity 124 day antiretroviral-experienced HIV-1-infected subject . By induce additional mutagenic event viral genome , viral decay accelerator KP-1212 may force virus exceed threshold nonviability .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Asymptomatic HIV1infected individual treatmentexperienced ART least 16 week . Have document prior nonsuppressive ART include least 1 NRTI , 1 NNRTI 2 PIs ; document prior ART resistance least 1 NRTI , 1 NNRTI 1 PI ; AND opinion investigator , , , effective treatment option available . Have &gt; 2,500 copies/mL HIV1 RNA screen . Have stable CD4 cell count ART &gt; 250 cells/mL screening . Have clinically significant finding screen evaluation . Have current recent opportunistic infection , opinion investigator , control medication . Have condition , opinion investigator , could compromise subject safety adherence protocol . Have document positive test hepatitis B surface antigen , receive antiviral therapy hepatitis C &lt; 6 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>viral</keyword>
	<keyword>Viral decay acceleration</keyword>
	<keyword>ART</keyword>
	<keyword>HAART</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>